INS and Hypoglycemia: Several clinical trials and observational studies have shown a decrease in glycated hemoglobin (HbA1c) and a lower incidence of hypoglycemia using CIPII, also reducing fasting insulin levels, in comparison with subcutaneous insulin delivery through CSII and MDI (4, 5).